Radiopharmaceutical · Kills target cells, directed at prostate-specific membrane antigen (FOLH1) · developed by Lantheus Medical Imaging
Lutetium Lu 177 zadavotide guraxetan is a radioconjugate in which a PSMA-targeting ligand is linked to the beta-emitting radioisotope lutetium-177. The ligand binds prostate-specific membrane antigen on tumor cells, delivering beta radiation that destroys them. It is studied in castration-resistant prostate cancer and metastatic renal cell carcinoma, including in combination with pembrolizumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06361810 | Phase 1/2 | Metastatic Renal Cell Carcinoma | Withdrawn | LNTH |
| NCT06033001 | N/A | Castration-Resistant Prostatic Cancer | Temporarily not available | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-Resistant Prostatic CancerMetastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →